age1 — 2015 Investments

1 investments dated 2015 · listed companies and verified rows first · show all

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsAtlas Venture Avoro Capital Advisors EcoR1 Capital Foresite Capital OrbiMed Ridgeback Capital +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.